<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="article-commentary" xml:lang="EN"><?properties open_access?><?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName ACSJournal-v102.dtd?><?SourceDTD.Version 1.02?><?ConverterInfo.XSLTName acs2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">ACS Med Chem Lett</journal-id><journal-id journal-id-type="iso-abbrev">ACS Med Chem Lett</journal-id><journal-id journal-id-type="publisher-id">ml</journal-id><journal-id journal-id-type="coden">amclct</journal-id><journal-title-group><journal-title>ACS Medicinal Chemistry Letters</journal-title></journal-title-group><issn pub-type="epub">1948-5875</issn><publisher><publisher-name>American Chemical
Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7269097</article-id><article-id pub-id-type="doi">10.1021/acsmedchemlett.0c00254</article-id><article-categories><subj-group><subject>Viewpoint</subject></subj-group></article-categories><title-group><article-title>Exploiting Existing Molecular Scaffolds for Long-Term
COVID Treatment</article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><name><surname>Kumar</surname><given-names>Krishna</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath2"><name><surname>Lupoli</surname><given-names>Tania J.</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><aff id="aff1"><label>&#x02020;</label>Department
of Chemistry, <institution>Tufts University</institution>, Medford, Massachusetts 02155, <country>United States</country></aff><aff id="aff2"><label>&#x02021;</label>Department
of Chemistry, <institution>New York University</institution>, New York, New York 10003, <country>United States</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email: <email>tjl229@nyu.edu</email>.</corresp></author-notes><pub-date pub-type="epub"><day>03</day><month>06</month><year>2020</year></pub-date><pub-date pub-type="collection"><day>09</day><month>07</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>03</day><month>06</month><year>2020</year></pub-date><volume>11</volume><issue>7</issue><fpage>1357</fpage><lpage>1360</lpage><history/><permissions><copyright-statement>Copyright &#x000a9; 2020 American Chemical
Society</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>American Chemical
Society</copyright-holder><license><license-p>This article is made available via the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/page/vi/chemistry_coronavirus_research">ACS COVID-19 subset</ext-link> for unrestricted RESEARCH re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml0c00254_0001" id="ab-tgr1"/></p><p>Discovery and development of COVID-19
prophylactics and treatments
remains a global imperative. This perspective provides an overview
of important molecular pathways involved in the viral life cycle of
SARS-CoV-2, the infectious agent of COVID-19. We highlight past and
recent findings in essential coronavirus proteins, including RNA polymerase
machinery, proteases, and fusion proteins, that offer opportunities
for the design of novel inhibitors of SARS-CoV-2 infection. By discussing
the current inventory of viral inhibitors, we identify molecular scaffolds
that may be improved by medicinal chemistry efforts for effective
therapeutics to treat current and future coronavirus-caused diseases.</p></abstract><kwd-group><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>replication</kwd><kwd>fusion</kwd><kwd>protease</kwd><kwd>antivirals</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>ml0c00254</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>ml0c00254</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><p id="sec1">Most of the world&#x02019;s initial
efforts to treat Coronavirus Disease 2019 (COVID-19) have focused
on the repurposing of approved drugs. This approach is warranted,
as we seek quick solutions to a pandemic, caused by Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2). The recent announcement of the
antiviral remdesivir as the first U.S. Food and Drug Administration
(FDA) approved drug for the treatment of patients suffering from severe
symptoms of COVID-19 affirms this approach. Anthony Fauci, the director
of the National Institute of Allergy and Infectious Disease (NIAID)
said that the completed clinical trial with remdesivir proved &#x0201c;that
a drug can block this virus&#x0201d;, although this drug alone is not
a &#x0201c;magic bullet&#x0201d; for COVID-19.</p><p>Without the ability
to accurately predict a timeline for a vaccine,
we need additional clinical candidates to build an arsenal against
SARS-CoV infections. Related coronaviruses, SARS-CoV-1 and MERS-CoV
(Middle East Respiratory Syndrome Coronavirus), caused serious, albeit
less widespread, health epidemics starting in 2002 and 2012. The occurrence
of multiple outbreaks further motivates us to annotate therapeutic
targets for other coronavirus-caused diseases that might develop in
the future. Similar to the treatment of influenza, we would benefit
from multiprong defense tactics that include both vaccines and therapeutic
agents. Many recent scientific reviews and essays have outlined vaccine
efforts, as well as viral and host targets that are the focus of current
campaigns aimed at redirecting clinically used compounds for COVID-19.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup></p><p>Here, we outline viral pathways that contain
druggable targets
currently overlooked and propose general mechanisms to disrupt these
pathways. We begin with a short primer on the SARS-CoV-2 viral life
cycle and an overview of existing drugs that are the subject of current
clinical trials around the world. We then focus on alternative druggable
targets largely within the viral replicase machinery, as well as viral
entry and proteolytic processing pathways. Our proposed strategies
for blocking these pathways are informed by past and current work
on inhibitors of SARS-CoV and MERS-CoV, as well as other successful
antivirals. We hope to engage the medicinal chemistry community with
ideas for novel therapeutic targets in order to develop <italic>new
drugs</italic> to specifically disarm coronaviruses in the host.</p><sec id="sec2"><title>Overview
of the Viral Life Cycle</title><p>The genome organization of SARS-CoV-2
is similar to that of other
members of the &#x003b2;-coronavirus family that also include SARS-CoV-1
and MERS-CoV.<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> The viral RNA-encoded proteins
can be divided into two main classes: structural and nonstructural
proteins (nsps). The structural proteins (spike, envelope, membrane,
nucleocapsid, and hemagglutinin esterase) form the viral particle
and play additional functional roles during infection. Viral infection
begins with an interaction between the viral spike glycoprotein (S
protein) and a receptor, angiotensin-converting enzyme 2 (ACE2), on
the host cell surface (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>). ACE2 is expressed in various cell types, including those
in the lungs. Host proteases in the membrane are important in this
process;<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> namely, a cellular serine protease,
called transmembrane serine protease 2 (TMPRSS2) is known to prime
the trimer of S protein on the viral particle surface prior to cell
entry. Cleavage of S protein into two subunits is required for the
process of viral and host membrane fusion prior to viral uptake by
an endocytic mechanism.</p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Overview of the proposed viral life cycle of
SARS-CoV-2, the infectious
agent of COVID-19. Both viral and host machinery are essential for
viral infection, replication, reassembly, and egress. Remdesivir,
the only FDA approved drug for COVID-19 treatment, blocks RNA replication.
Highlighted are points of viral interference that have not been widely
exploited: (1) inhibition of additional components of the viral replication&#x02013;transcription
complex (RTC); (2) development of new modes of disrupting viral protease
activities; and (3) exploration of peptide-based inhibitors to prevent
host&#x02013;viral membrane fusion.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml0c00254_0002" id="GRAPHIC-d7e186-autogenerated" position="float"/></fig><p>Following
engulfment and subsequent release from the endosome,
viral genetic material is released into the host cytoplasm prior to
translation of the single stranded viral RNA into long polypeptides
that contain the nsps. Viral polypeptides are predicted to be cleaved
into 16 individual nsps through an autoprocessing mechanism.<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> There are two cysteine-like proteases expressed
as part of these polypeptides: one is a papain-like protease (PLP),
known as the accessory protease; the other is a chymotrypsin-like
protease (3CL<sup>pro</sup>), known as the main protease. 3CL<sup>pro</sup> cleaves itself and processes the remaining polypeptide
into nsps 7&#x02013;16, which make up the RNA replication-transcription
complex (RTC). Several components of the RTC aid the RNA-dependent
RNA polymerase (RdRP), which is responsible for replicating additional
copies of the RNA genome and transcribing multiple mRNA fragments
that encode either structural or accessory proteins. Following multiple
cycles of replication and translation, the viral particle assembles
and exits the cell though a budding mechanism known as scission. It
is thought that &#x003b2;-coronaviruses rely on the host cell&#x02019;s
endosomal sorting complex required for transport (ESCRT), but the
exact method of egress is still not known.<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> Full scission from the host cell releases the virus to infect more
cells and continue to replicate.</p></sec><sec id="sec3"><title>Known Drugs in Clinical
Trials for COVID-19 Target the Viral
Life Cycle</title><p>The World Health Organization (WHO) and federal
agencies are largely
focused on clinical trials for preapproved drugs that are proposed
to target some aspect of the viral life cycle described above (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>). The NIH now lists
over a thousand ongoing clinical trials for treatments relating to
COVID-19. The WHO is currently conducting a worldwide trial (&#x0201c;SOLIDARITY&#x0201d;)
by focusing on four promising COVID-19 treatments: remdesivir; lopinavir/ritonavir
with and without Interferon &#x003b2;-1a (to help stimulate the immune
system); and hydroxychloroquine (this last treatment has currently
been paused).</p><p>The FDA-approved COVID-19 drug, remdesivir, is
a nucleotide analog
originally developed to treat Ebola infections (caused by another
single-stranded RNA virus) and recently shown to inhibit the SARS-CoV-2
RdRP.<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> The FDA has issued an emergency
use authorization of hydroxychloroquine and chloroquine, both of which
are approved to treat malaria and various autoimmune disorders, and
might function by disrupting endosome-mediated entry or egress of
the virus.<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> Lopinavir-ritonavir are HIV
protease inhibitors that are hypothesized to inhibit SARS-CoV 3CL<sup>pro</sup>.<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> In addition to small molecule
inhibitor candidates, various clinical trials are exploring the effect
of known antibody therapies on COVID-19 progression or plan to test
antibodies raised against viral proteins.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup></p></sec><sec id="sec4"><title>Viral RNA Replicase Machinery Contains Alternative Viable Targets</title><p>The success of remdesivir in clinical trials, although limited,
suggests that inhibition of viral replication is a viable strategy
for the treatment of COVID-19. Importantly, it takes more than a single
polymerase to replicate the viral genome and ensure pathogenicity.
SARS-CoV-2 is thought to involve up to nine nsps in the RTC.<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> Key players include the RdRP (nsp12), helicase
(nsp13), and proposed polymerase cofactors/primase(s) (nsp 7, 8).
To our knowledge, these proteins are not targets in current COVID-19
clinical trials. The viral RTC proteins are expressed in the cytoplasm
and so are more accessible that their host counterparts in the nucleus.</p><p>Coronavirus helicases are motor proteins necessary for unwinding
double-stranded RNA, which form secondary structures, in order for
replication and translation to occur. Since viral helicases typically
share low homology with human DNA helicases, specific helicase inhibitors
are unlikely to be toxic to the host.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> The
amino acid sequence of SARS-CoV-1 helicase is identical to that found
in SARS-CoV-2; hence, a solved crystal structure of the SARS-CoV-1
helicase provides opportunities for rational drug design.<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> The Lupoli and Zhang laboratories (NYU, Chemistry)
are currently using this structure to design small molecule ligands
for computationally predicted binding pockets. In addition to a nucleotide
binding site, the SARS-CoV helicase contains a zinc binding domain
with three zinc fingers, and mutation of residues linking this domain
to the helicase core domain were shown to cause a deficiency in nucleic
acid unwinding.<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> As a result, there are
multiple sites for disruption of helicase activity.</p><p>Unique among
other RNA viruses, coronaviruses are believed to have
two nsps with RNA polymerase activity. The canonical RdRP is primer-dependent
for optimal activity, while the second polymerase (nsp8) is hypothesized
to be a primase.<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> The primary sequences
of nsp7, 8 and RdRP are &#x02265;96% identical in SARS-CoV-1 and CoV-2.
A solved cryoelectron microscopy structure of the SARS-CoV-1 RTC complex
has shown that interactions between RdRP, nsp7 and 8 are essential
for activity.<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> Interestingly, the main
RdRP also has an N-terminal kinase-like domain that may carry out
nucleotidyltransfer reactions. Disruption of this site or any member
of this complex represents a novel opportunity for chemical interference.</p><p>Inhibition of helicase or primase activities has been pursued as
an antiviral approach in the past and has been reviewed in detail
elsewhere.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> Importantly, herpes simplex
virus (HSV) helicase UL5 is a member of the same helicase super family
1 (SF1) as SARS-CoV-2 nsp13. In 2002, Boehringer-Ingelheim<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> and Bayer<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> independently
reported on inhibitors of the HSV helicase&#x02013;primase complex
that were comparative to approved antivirals for HSV. Boehringer-Ingelheim&#x02019;s
aminothiazoylphenyl-based inhibitors of HSV helicase&#x02013;primase,
namely, BILS 179 (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>, compound <bold>1</bold>), exhibit nanomolar antiviral activity
and are selective for HSV infection in mouse models. The clinically
used amenamevir (<bold>2</bold>), another herpes antiviral, also targets
in the helicase&#x02013;primase at nanomolar concentrations.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> The most promising inhibitor of SARS-CoV-1 helicase,
SSYA10-001 (<bold>3</bold>), which shows micromolar activity against
SARS-CoV-1 and MERS-CoV infections in vitro, was awarded a US patent
in 2014.<sup><xref ref-type="bibr" rid="ref13">13</xref>,<xref ref-type="bibr" rid="ref14">14</xref></sup> Given the conservation of helicase sequences
in SARS-CoV-1 and CoV-2, this inhibitor will likely serve as a useful
starting point for future design of coronavirus helicase modulators.</p><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Select
chemical scaffolds for viral target disruption. Existing
viral helicase inhibitors (<bold>1</bold>&#x02013;<bold>3</bold>),<sup><xref ref-type="bibr" rid="ref8">8</xref>,<xref ref-type="bibr" rid="ref11">11</xref>,<xref ref-type="bibr" rid="ref14">14</xref></sup> including the SARS-CoV-1 helicase
binder SSYA10-001 (<bold>2</bold>) and viral protease inhibitors (<bold>4</bold>&#x02013;<bold>5</bold>).<sup><xref ref-type="bibr" rid="ref15">15</xref>,<xref ref-type="bibr" rid="ref17">17</xref></sup></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml0c00254_0003" id="GRAPHIC-d7e303-autogenerated" position="float"/></fig></sec><sec id="sec5"><title>Novel
Strategies for Targeting Viral Proteases</title><p>Although many host
proteases are deemed essential for late-stage
processing of proteins translated from viral RNA, viral 3CL<sup>pro</sup> (also called M<sup>pro</sup>) and PLP have emerged as popular targets
for COVID-19. HIV protease inhibitors lopinavir and ritonavir, included
in the SOLIDARITY trial despite mixed reviews in the clinic, have
been predicted to bind SARS-CoV-1 and CoV-2 3CL<sup>pro</sup> (96%
sequence identity) based on computational studies.<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> While HIV proteases are aspartic proteases, coronavirus
proteases are members of the cysteine protease family. Given that
approximately a quarter of human proteases are predicted to belong
to this class, design of specific viral inhibitors remains a challenge.
Fortunately, to aid in the rational design of inhibitors, a crystal
structure of SARS-CoV-2 3CL<sup>pro</sup> was reported recently.<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> As part of this work, peptidomimetic compounds
(&#x003b1;-keto amides), previously designed against &#x003b2;- and &#x003b1;-coronaviruses,
were modified for stability. The most promising mimetic (<bold>4</bold>) inhibited SARS-CoV-2 replication in human lung cells at micromolar
concentrations and therefore requires further improvement. Carboxamide
and acetamide scaffold structures have been shown to inhibit 3CL<sup>pro</sup> of SARS-CoV-1, along with other inhibitors that have been
reviewed elsewhere.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> Another viable viral
target, PLP, shows lower sequence conservation between SARS-CoV-1
and CoV-2 (76% homology). Notably, PLP possesses additional activities
beyond polypeptide processing, such as deubiquitination and cleavage
of the ubiquitin-like modifier, ISG15. These PLP-dependent activities
contribute to viral immune evasion in the host. Inhibitors of PLP-mediated
ISG15 cleavage activity, such as compound <bold>5</bold>, have EC<sub>50</sub> values of &#x0223c;10 uM against SARS-CoV-1 infection in
cell culture with no associated cytotoxicity.<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> Structural information and the noted unique features of SARS-CoV
cysteine proteases can be exploited for selective inhibition, but
existing scaffolds still require optimization to disable SARS-CoV-2
infections in the host.</p></sec><sec id="sec6"><title>Peptide-Based Approaches for Membrane Fusion
Inhibitors</title><p>The S proteins of SARS-CoV-1 and CoV-2 share 76%
overall sequence
identity, yet the receptor binding domain (RBD) of the latter has
10&#x02013;20-fold higher affinity to the human ACE2 receptor protein.<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> After the RBD binds ACE2, two heptad repeat
domains, HR1 and HR2, interact to form a six-helical bundle, and in
so doing bring the viral and host membrane proximal to one another
resulting in fusion. This fusion process is essential for viral entry.
Design of &#x0201c;coiled coil&#x0201d; heptad repeat-based peptides
provides an avenue for drug design that can easily be tailored to
respond to mutations that will arise in future S proteins. Using a
recently solved crystal structure of the HR1 and HR2 domains of the
SARS-CoV-2 S protein, lipidated peptide fusion inhibitors have been
designed that inhibit pseudovirus infection of cells with IC<sub>50</sub> values in the single-digit nanomolar range.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> Targeting membrane fusion with peptide-based inhibitors offers opportunities
and flexibility for entry inhibition in future coronavirus strains,
but the cost and possible side effects may be a deterrent for widespread
global use.</p></sec><sec id="sec7"><title>Conclusions</title><p>We envision that in the coming months and
years, there will be
three phases of therapeutic intervention for COVID-19: (1) repurposing
of existing drugs as treatments and prophylactics; (2) the development
of vaccines; and, (3) as the threat of a mutated virus looms large,
the development of an arsenal of compounds that are available against
other targets to sustain a defense against widespread infection. The
reservoir of targets and available compounds against this and related
viruses described in this perspective is a resource that medicinal
chemists are encouraged to explore further.</p></sec></body><back><notes notes-type="disclosure" id="notes-100"><p>Views expressed in
this editorial are those of the authors and not necessarily the views
of the ACS.</p></notes><notes notes-type="COI-statement" id="NOTES-d7e367-autogenerated"><p>The authors declare no
competing financial interest.</p></notes><ack><title>Acknowledgments</title><p>T.J.L. would like to thank Alexa Harnagel, Brock Nelson and
Jordan Hosfelt for initial literature research.</p></ack><glossary id="dl1"><def-list><title>Abbreviations</title><def-item><term>ACE2</term><def><p>angiotensin-converting enzyme 2</p></def></def-item><def-item><term>COVID-19</term><def><p>Coronavirus
Disease 2019</p></def></def-item><def-item><term>SARS-CoV</term><def><p>Severe Acute Respiratory Syndrome Coronavirus</p></def></def-item><def-item><term>S protein</term><def><p>spike glycoprotein</p></def></def-item><def-item><term>nsp(s)</term><def><p>nonstructural protein(s)</p></def></def-item><def-item><term>RTC</term><def><p>RNA replication-transcription complex</p></def></def-item><def-item><term>RdRP</term><def><p>RNA-dependent
RNA polymerase</p></def></def-item><def-item><term>PLP</term><def><p>papain-like protease</p></def></def-item><def-item><term>3CL<sup>pro</sup></term><def><p>chymotrypsin-like protease</p></def></def-item><def-item><term>HR</term><def><p>heptad repeat</p></def></def-item><def-item><term>RBD</term><def><p>receptor binding domain</p></def></def-item><def-item><term>WHO</term><def><p>World Health Organization</p></def></def-item><def-item><term>FDA</term><def><p>Food and Drug Administration</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal" id="cit1"><name><surname>Liu</surname><given-names>C.</given-names></name>; <name><surname>Zhou</surname><given-names>Q.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Garner</surname><given-names>L. V.</given-names></name>; <name><surname>Watkins</surname><given-names>S. P.</given-names></name>; <name><surname>Carter</surname><given-names>L. J.</given-names></name>; <name><surname>Smoot</surname><given-names>J.</given-names></name>; <name><surname>Gregg</surname><given-names>A. C.</given-names></name>; <name><surname>Daniels</surname><given-names>A. D.</given-names></name>; <name><surname>Jervey</surname><given-names>S.</given-names></name>; <name><surname>Albaiu</surname><given-names>D.</given-names></name>
<article-title>Research and
Development on Therapeutic
Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases</article-title>. <source>ACS Cent. Sci.</source>
<year>2020</year>, <volume>6</volume> (<issue>3</issue>), <fpage>315</fpage>&#x02013;<lpage>331</lpage>. <pub-id pub-id-type="doi">10.1021/acscentsci.0c00272</pub-id>.<pub-id pub-id-type="pmid">32226821</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal" id="cit2"><name><surname>Chan</surname><given-names>J. F. W.</given-names></name>; <name><surname>Kok</surname><given-names>K. H.</given-names></name>; <name><surname>Zhu</surname><given-names>Z.</given-names></name>; <name><surname>Chu</surname><given-names>H.</given-names></name>; <name><surname>To</surname><given-names>K. K.</given-names></name>; <name><surname>Yuan</surname><given-names>S.</given-names></name>; <name><surname>Yuen</surname><given-names>K. Y.</given-names></name>
<article-title>Genomic characterization
of the 2019
novel human-pathogenic coronavirus isolated from a patient with atypical
pneumonia after visiting Wuhan</article-title>. <source>Emerging Microbes
Infect.</source>
<year>2020</year>, <volume>9</volume>, <fpage>221</fpage>&#x02013;<lpage>236</lpage>. <pub-id pub-id-type="doi">10.1080/22221751.2020.1719902</pub-id>.</mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name><surname>Schoeman</surname><given-names>D.</given-names></name>; <name><surname>Fielding</surname><given-names>B. C.</given-names></name>
<article-title>Coronavirus envelope protein: current knowledge</article-title>. <source>Virol. J.</source>
<year>2019</year>, <volume>16</volume> (<issue>1</issue>), <fpage>69</fpage><pub-id pub-id-type="doi">10.1186/s12985-019-1182-0</pub-id>.<pub-id pub-id-type="pmid">31133031</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name><surname>Ziebuhr</surname><given-names>J.</given-names></name>; <name><surname>Snijder</surname><given-names>E. J.</given-names></name>; <name><surname>Gorbalenya</surname><given-names>A. E.</given-names></name>
<article-title>Virus-encoded
proteinases and proteolytic
processing in the Nidovirales</article-title>. <source>J. Gen. Virol.</source>
<year>2000</year>, <volume>81</volume> (<issue>Pt 4</issue>), <fpage>853</fpage>&#x02013;<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1099/0022-1317-81-4-853</pub-id>.<pub-id pub-id-type="pmid">10725411</pub-id></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><person-group person-group-type="allauthors"><name><surname>Yin</surname><given-names>W.</given-names></name>; <name><surname>Mao</surname><given-names>C.</given-names></name>; <name><surname>Luan</surname><given-names>X.</given-names></name>; <name><surname>Shen</surname><given-names>D. D.</given-names></name>; <name><surname>Shen</surname><given-names>Q.</given-names></name>; <name><surname>Su</surname><given-names>H.</given-names></name>; <name><surname>Wang</surname><given-names>X.</given-names></name>; <name><surname>Zhou</surname><given-names>F.</given-names></name>; <name><surname>Zhao</surname><given-names>W.</given-names></name>; <name><surname>Gao</surname><given-names>M.</given-names></name>; <name><surname>Chang</surname><given-names>S.</given-names></name>; <name><surname>Xie</surname><given-names>Y. C.</given-names></name>; <name><surname>Tian</surname><given-names>G.</given-names></name>; <name><surname>Jiang</surname><given-names>H. W.</given-names></name>; <name><surname>Tao</surname><given-names>S. C.</given-names></name>; <name><surname>Shen</surname><given-names>J.</given-names></name>; <name><surname>Jiang</surname><given-names>Y.</given-names></name>; <name><surname>Jiang</surname><given-names>H.</given-names></name>; <name><surname>Xu</surname><given-names>Y.</given-names></name>; <name><surname>Zhang</surname><given-names>S.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Xu</surname><given-names>H. E.</given-names></name></person-group><article-title>Structural basis for inhibition of the RNA-dependent
RNA polymerase from SARS-CoV-2 by remdesivir</article-title>. <source>Science</source><year>2020</year>, <fpage>eabc1560</fpage><pub-id pub-id-type="doi">10.1126/science.abc1560</pub-id>.</mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name><surname>Schrezenmeier</surname><given-names>E.</given-names></name>; <name><surname>D&#x000f6;rner</surname><given-names>T.</given-names></name>
<article-title>Mechanisms
of action of hydroxychloroquine and chloroquine:
implications for rheumatology</article-title>. <source>Nat. Rev. Rheumatol.</source>
<year>2020</year>, <volume>16</volume> (<issue>3</issue>), <fpage>155</fpage>&#x02013;<lpage>166</lpage>. <pub-id pub-id-type="doi">10.1038/s41584-020-0372-x</pub-id>.<pub-id pub-id-type="pmid">32034323</pub-id></mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><person-group person-group-type="allauthors"><name><surname>Nutho</surname><given-names>B.</given-names></name>; <name><surname>Mahalapbutr</surname><given-names>P.</given-names></name>; <name><surname>Hengphasatporn</surname><given-names>K.</given-names></name>; <name><surname>Pattaranggoon</surname><given-names>N. C.</given-names></name>; <name><surname>Simanon</surname><given-names>N.</given-names></name>; <name><surname>Shigeta</surname><given-names>Y.</given-names></name>; <name><surname>Hannongbua</surname><given-names>S.</given-names></name>; <name><surname>Rungrotmongkol</surname><given-names>T.</given-names></name></person-group><article-title>Why are lopinavir
and ritonavir effective against the newly emerged coronavirus 2019?
Atomistic insights into the inhibitory mechanisms</article-title>. <source>Biochemistry</source><year>2020</year>, <volume>59</volume>, <fpage>1769</fpage><pub-id pub-id-type="doi">10.1021/acs.biochem.0c00160</pub-id>.<pub-id pub-id-type="pmid">32293875</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name><surname>Shadrick</surname><given-names>W. R.</given-names></name>; <name><surname>Ndjomou</surname><given-names>J.</given-names></name>; <name><surname>Kolli</surname><given-names>R.</given-names></name>; <name><surname>Mukherjee</surname><given-names>S.</given-names></name>; <name><surname>Hanson</surname><given-names>A. M.</given-names></name>; <name><surname>Frick</surname><given-names>D. N.</given-names></name>
<article-title>Discovering new
medicines targeting
helicases: challenges and recent progress</article-title>. <source>J.
Biomol. Screening</source>
<year>2013</year>, <volume>18</volume> (<issue>7</issue>), <fpage>761</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1177/1087057113482586</pub-id>.</mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>Jia</surname><given-names>Z.</given-names></name>; <name><surname>Yan</surname><given-names>L.</given-names></name>; <name><surname>Ren</surname><given-names>Z.</given-names></name>; <name><surname>Wu</surname><given-names>L.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Guo</surname><given-names>J.</given-names></name>; <name><surname>Zheng</surname><given-names>L.</given-names></name>; <name><surname>Ming</surname><given-names>Z.</given-names></name>; <name><surname>Zhang</surname><given-names>L.</given-names></name>; <name><surname>Lou</surname><given-names>Z.</given-names></name>; <name><surname>Rao</surname><given-names>Z.</given-names></name>
<article-title>Delicate structural coordination of the Severe Acute Respiratory
Syndrome Coronavirus nsp13 upon ATP hydrolysis</article-title>. <source>Nucleic Acids Res.</source>
<year>2019</year>, <volume>47</volume> (<issue>12</issue>), <fpage>6538</fpage>&#x02013;<lpage>6550</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkz409</pub-id>.<pub-id pub-id-type="pmid">31131400</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name><surname>Kirchdoerfer</surname><given-names>R. N.</given-names></name>; <name><surname>Ward</surname><given-names>A. B.</given-names></name>
<article-title>Structure of the
SARS-CoV nsp12 polymerase bound to
nsp7 and nsp8 co-factors</article-title>. <source>Nat. Commun.</source>
<year>2019</year>, <volume>10</volume> (<issue>1</issue>), <fpage>2342</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-10280-3</pub-id>.<pub-id pub-id-type="pmid">31138817</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name><surname>Crute</surname><given-names>J. J.</given-names></name>; <name><surname>Grygon</surname><given-names>C. A.</given-names></name>; <name><surname>Hargrave</surname><given-names>K. D.</given-names></name>; <name><surname>Simoneau</surname><given-names>B.</given-names></name>; <name><surname>Faucher</surname><given-names>A. M.</given-names></name>; <name><surname>Bolger</surname><given-names>G.</given-names></name>; <name><surname>Kibler</surname><given-names>P.</given-names></name>; <name><surname>Liuzzi</surname><given-names>M.</given-names></name>; <name><surname>Cordingley</surname><given-names>M. G.</given-names></name>
<article-title>Herpes
simplex virus helicase-primase inhibitors are active in animal models
of human disease</article-title>. <source>Nat. Med.</source>
<year>2002</year>, <volume>8</volume> (<issue>4</issue>), <fpage>386</fpage>&#x02013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1038/nm0402-386</pub-id>.<pub-id pub-id-type="pmid">11927945</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name><surname>Kleymann</surname><given-names>G.</given-names></name>; <name><surname>Fischer</surname><given-names>R.</given-names></name>; <name><surname>Betz</surname><given-names>U. A.</given-names></name>; <name><surname>Hendrix</surname><given-names>M.</given-names></name>; <name><surname>Bender</surname><given-names>W.</given-names></name>; <name><surname>Schneider</surname><given-names>U.</given-names></name>; <name><surname>Handke</surname><given-names>G.</given-names></name>; <name><surname>Eckenberg</surname><given-names>P.</given-names></name>; <name><surname>Hewlett</surname><given-names>G.</given-names></name>; <name><surname>Pevzner</surname><given-names>V.</given-names></name>; <name><surname>Baumeister</surname><given-names>J.</given-names></name>; <name><surname>Weber</surname><given-names>O.</given-names></name>; <name><surname>Henninger</surname><given-names>K.</given-names></name>; <name><surname>Keldenich</surname><given-names>J.</given-names></name>; <name><surname>Jensen</surname><given-names>A.</given-names></name>; <name><surname>Kolb</surname><given-names>J.</given-names></name>; <name><surname>Bach</surname><given-names>U.</given-names></name>; <name><surname>Popp</surname><given-names>A.</given-names></name>; <name><surname>M&#x000e4;ben</surname><given-names>J.</given-names></name>; <name><surname>Frappa</surname><given-names>I.</given-names></name>; <name><surname>Haebich</surname><given-names>D.</given-names></name>; <name><surname>Lockhoff</surname><given-names>O.</given-names></name>; <name><surname>R&#x000fc;bsamen-Waigmann</surname><given-names>H.</given-names></name>
<article-title>New helicase-primase
inhibitors as
drug candidates for the treatment of herpes simplex disease</article-title>. <source>Nat. Med.</source>
<year>2002</year>, <volume>8</volume> (<issue>4</issue>), <fpage>392</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/nm0402-392</pub-id>.<pub-id pub-id-type="pmid">11927946</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name><surname>Adedeji</surname><given-names>A. O.</given-names></name>; <name><surname>Singh</surname><given-names>K.</given-names></name>; <name><surname>Kassim</surname><given-names>A.</given-names></name>; <name><surname>Coleman</surname><given-names>C. M.</given-names></name>; <name><surname>Elliott</surname><given-names>R.</given-names></name>; <name><surname>Weiss</surname><given-names>S. R.</given-names></name>; <name><surname>Frieman</surname><given-names>M. B.</given-names></name>; <name><surname>Sarafianos</surname><given-names>S. G.</given-names></name>
<article-title>Evaluation
of SSYA10&#x02013;001 as a replication inhibitor of severe acute respiratory
syndrome, mouse hepatitis, and Middle East respiratory syndrome coronaviruses</article-title>. <source>Antimicrob. Agents Chemother.</source>
<year>2014</year>, <volume>58</volume> (<issue>8</issue>), <fpage>4894</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.02994-14</pub-id>.<pub-id pub-id-type="pmid">24841268</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="patent" id="cit14"><person-group person-group-type="allauthors"><name><surname>Sarafianos</surname><given-names>G. S.</given-names></name>; <name><surname>Adedeji</surname><given-names>O. A.</given-names></name>; <name><surname>Singh</surname><given-names>K.</given-names></name></person-group><source>Suppression
of Sars Replication by Sars Helicase Inhibitors</source>. US Patent
WO <patent>20140005241</patent>, January 2, <year>2014</year>.</mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name><surname>Zhang</surname><given-names>L.</given-names></name>; <name><surname>Lin</surname><given-names>D.</given-names></name>; <name><surname>Sun</surname><given-names>X.</given-names></name>; <name><surname>Curth</surname><given-names>U.</given-names></name>; <name><surname>Drosten</surname><given-names>C.</given-names></name>; <name><surname>Sauerhering</surname><given-names>L.</given-names></name>; <name><surname>Becker</surname><given-names>S.</given-names></name>; <name><surname>Rox</surname><given-names>K.</given-names></name>; <name><surname>Hilgenfeld</surname><given-names>R.</given-names></name>
<article-title>Crystal structure
of SARS-CoV-2 main protease provides a basis for design of improved
&#x003b1;-ketoamide inhibitors</article-title>. <source>Science</source>
<year>2020</year>, <volume>368</volume> (<issue>6489</issue>), <fpage>409</fpage>&#x02013;<lpage>412</lpage>. <pub-id pub-id-type="doi">10.1126/science.abb3405</pub-id>.<pub-id pub-id-type="pmid">32198291</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name><surname>Pillaiyar</surname><given-names>T.</given-names></name>; <name><surname>Manickam</surname><given-names>M.</given-names></name>; <name><surname>Namasivayam</surname><given-names>V.</given-names></name>; <name><surname>Hayashi</surname><given-names>Y.</given-names></name>; <name><surname>Jung</surname><given-names>S. H.</given-names></name>
<article-title>An overview
of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease
inhibitors: Peptidomimetics and small molecule Chemotherapy</article-title>. <source>J. Med. Chem.</source>
<year>2016</year>, <volume>59</volume> (<issue>14</issue>), <fpage>6595</fpage>&#x02013;<lpage>628</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b01461</pub-id>.<pub-id pub-id-type="pmid">26878082</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name><surname>Ratia</surname><given-names>K.</given-names></name>; <name><surname>Pegan</surname><given-names>S.</given-names></name>; <name><surname>Takayama</surname><given-names>J.</given-names></name>; <name><surname>Sleeman</surname><given-names>K.</given-names></name>; <name><surname>Coughlin</surname><given-names>M.</given-names></name>; <name><surname>Baliji</surname><given-names>S.</given-names></name>; <name><surname>Chaudhuri</surname><given-names>R.</given-names></name>; <name><surname>Fu</surname><given-names>W.</given-names></name>; <name><surname>Prabhakar</surname><given-names>B. S.</given-names></name>; <name><surname>Johnson</surname><given-names>M. E.</given-names></name>; <name><surname>Baker</surname><given-names>S. C.</given-names></name>; <name><surname>Ghosh</surname><given-names>A. K.</given-names></name>; <name><surname>Mesecar</surname><given-names>A. D.</given-names></name>
<article-title>A noncovalent
class of papain-like protease/deubiquitinase inhibitors blocks SARS
virus replication</article-title>. <source>Proc. Natl. Acad. Sci. U.
S. A.</source>
<year>2008</year>, <volume>105</volume> (<issue>42</issue>), <fpage>16119</fpage>&#x02013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0805240105</pub-id>.<pub-id pub-id-type="pmid">18852458</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name><surname>Wrapp</surname><given-names>D.</given-names></name>; <name><surname>Wang</surname><given-names>N.</given-names></name>; <name><surname>Corbett</surname><given-names>K. S.</given-names></name>; <name><surname>Goldsmith</surname><given-names>J. A.</given-names></name>; <name><surname>Hsieh</surname><given-names>C. L.</given-names></name>; <name><surname>Abiona</surname><given-names>O.</given-names></name>; <name><surname>Graham</surname><given-names>B. S.</given-names></name>; <name><surname>McLellan</surname><given-names>J. S.</given-names></name>
<article-title>Cryo-EM
structure of the 2019-nCoV spike in the prefusion conformation</article-title>. <source>Science</source>
<year>2020</year>, <volume>367</volume> (<issue>6483</issue>), <fpage>1260</fpage>&#x02013;<lpage>1263</lpage>. <pub-id pub-id-type="doi">10.1126/science.abb2507</pub-id>.<pub-id pub-id-type="pmid">32075877</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name><surname>Xia</surname><given-names>S.</given-names></name>; <name><surname>Liu</surname><given-names>M.</given-names></name>; <name><surname>Wang</surname><given-names>C.</given-names></name>; <name><surname>Xu</surname><given-names>W.</given-names></name>; <name><surname>Lan</surname><given-names>Q.</given-names></name>; <name><surname>Feng</surname><given-names>S.</given-names></name>; <name><surname>Qi</surname><given-names>F.</given-names></name>; <name><surname>Bao</surname><given-names>L.</given-names></name>; <name><surname>Du</surname><given-names>L.</given-names></name>; <name><surname>Liu</surname><given-names>S.</given-names></name>; <name><surname>Qin</surname><given-names>C.</given-names></name>; <name><surname>Sun</surname><given-names>F.</given-names></name>; <name><surname>Shi</surname><given-names>Z.</given-names></name>; <name><surname>Zhu</surname><given-names>Y.</given-names></name>; <name><surname>Jiang</surname><given-names>S.</given-names></name>; <name><surname>Lu</surname><given-names>L.</given-names></name>
<article-title>Inhibition
of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent
pan-coronavirus fusion inhibitor targeting its spike protein that
harbors a high capacity to mediate membrane fusion</article-title>. <source>Cell Res.</source>
<year>2020</year>, <volume>30</volume> (<issue>4</issue>), <fpage>343</fpage>&#x02013;<lpage>355</lpage>. <pub-id pub-id-type="doi">10.1038/s41422-020-0305-x</pub-id>.<pub-id pub-id-type="pmid">32231345</pub-id></mixed-citation></ref></ref-list></back></article>